M Pascal Selected Research

M Pascal Research Topics

Disease

6	Hypersensitivity (Allergy) 07/2022 - 10/2012
4	Anaphylaxis (Anaphylactic Shock) 07/2022 - 05/2011
2	Shellfish Hypersensitivity 09/2021 - 06/2017
2	Egg Hypersensitivity (Egg Allergy) 04/2014 - 10/2013
2	Shock 08/2013 - 05/2012
2	Food Hypersensitivity (Food Allergy) 01/2013 - 10/2012
1	Chronic Urticaria 02/2022
1	Mast Cell Activation Syndrome 12/2021
1	COVID-19 01/2021
1	Asthma (Bronchial Asthma) 04/2020
1	Nut Hypersensitivity (Nut Allergy) 07/2016
1	Brain Death (Brain Dead) 08/2013
1	Wounds and Injuries (Trauma) 08/2013
1	Persistent Vegetative State (Vegetative State) 08/2013
1	Traumatic Brain Injuries (Traumatic Brain Injury) 08/2013
1	Spinal Cord Injuries (Spinal Cord Injury) 08/2013
1	Brain Hypoxia-Ischemia (Hypoxia Ischemia, Brain) 08/2013
1	Stroke (Strokes) 08/2013
1	Pulmonary Embolism 08/2013
1	Quadriplegia (Spastic Quadriplegia) 08/2013
1	Seasonal Allergic Rhinitis (Hay Fever) 10/2012
1	Thrombocytopenia (Thrombopenia) 05/2012
1	Hypoglycemia (Reactive Hypoglycemia) 05/2012
1	Sepsis (Septicemia) 05/2012
1	Anxiety Disorders (Anxiety Disorder) 01/2002
1	Heart Failure 01/2002
1	Inappropriate ADH Syndrome (SIADH) 01/2002
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2002
1	Neoplasms (Cancer) 01/2002
1	Fibrosis (Cirrhosis) 10/2000
1	Ascites 10/2000
1	Schistosomiasis (Bilharziasis) 01/2000
1	Infections 01/2000

Drug/Important Bio-Agent (IBA)

7	Immunoglobulin E (IgE)IBA 02/2022 - 10/2012
4	AllergensIBA 09/2021 - 10/2012
2	lipid transfer protein (glycolipid transfer protein)IBA 07/2022 - 01/2016
2	VaccinesIBA 01/2021 - 01/2013
1	Omalizumab (Xolair)FDA Link 02/2022
1	Tryptases (Tryptase)IBA 12/2021
1	Dermatophagoides pteronyssinus antigen p 2IBA 04/2020
1	Pyridinolcarbamate (P23)IBA 04/2020
1	Dermatophagoides pteronyssinus antigen p 1IBA 04/2020
1	Proteins (Proteins, Gene)FDA Link 07/2016
1	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 01/2016
1	acetylsalicylic acid lysinateIBA 01/2016
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2016
1	valdecoxib (Bextra)FDA Link 01/2016
1	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 01/2016
1	CrizotinibIBA 01/2015
1	Peptides (Polypeptides)IBA 01/2013
1	hypoxanthine arabinoside (ara-H)IBA 01/2013
1	HLA-DR Antigens (HLA-DR)IBA 01/2013
1	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 01/2013
1	Profilins (Profilin)IBA 10/2012
1	Pharmaceutical PreparationsIBA 05/2012
1	Lactic Acid (Lactate)FDA LinkGeneric 05/2012
1	Lipoproteins (Lipoprotein)IBA 05/2011
1	1- (5- chloro- 1- ((2,4- dimethoxyphenyl)sulfonyl)- 3- (2- methoxyphenyl)- 2- oxo- 2,3- dihydro- 1H- indol- 3- yl)- 4- hydroxy- N,N- dimethyl- 2- pyrrolidinecarboxamideIBA 01/2002
1	2-oxindole (oxindole)IBA 01/2002
1	Adrenocorticotropic Hormone (ACTH)FDA Link 01/2002
1	Vasopressins (Vasopressin)IBA 01/2002
1	Vasopressin Receptors (Arginine Vasopressin Receptor)IBA 01/2002
1	mozavaptanIBA 10/2000
1	niravolineIBA 10/2000
1	kappa Opioid Receptors (kappa Opioid Receptor)IBA 10/2000
1	SodiumIBA 10/2000
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2000
1	Biomarkers (Surrogate Marker)IBA 01/2000
1	AntioxidantsIBA 01/2000

Therapy/Procedure

1	Therapeutics 12/2021
1	Resuscitation 08/2013
1	Artificial Respiration (Mechanical Ventilation) 05/2012
1	Length of Stay 05/2012
1	Continuous Renal Replacement Therapy 05/2012
1	Hemodiafiltration 05/2012
1	Oral Administration 10/2000